Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

Area of Science:

• Infectious Diseases
• Nephrology
• Pharmacology

Background:

• Severe sepsis poses a significant challenge, particularly when caused by panresistant pathogens like Pseudomonas aeruginosa.
• Standard therapies, including colistin and beta-lactams, can be ineffective against multidrug-resistant organisms.
• Aminoglycosides, such as amikacin, are often reserved due to toxicity concerns but may be necessary for resistant infections.

Observation:

• Two patients with severe sepsis and panresistant Pseudomonas aeruginosa showed clinical deterioration despite conventional treatments.
• Treatment with high-dose amikacin (25-50 mg/kg/day) achieved a peak/MIC ratio of 8-10 (MIC=16 μg/ml).
• Continuous venovenous hemodiafiltration (CVVHDF) was administered concurrently without adverse effects on renal function.

Findings:

• High-dose amikacin therapy resulted in the cure of both patients with severe sepsis.
• The combination of high-dose amikacin and CVVHDF was well-tolerated, with no observed deterioration in renal function.
• Achieving a high peak/MIC ratio for amikacin was crucial for therapeutic success.

Implications:

• High-dose aminoglycoside therapy, particularly amikacin, can be a viable option for treating severe infections caused by panresistant Pseudomonas aeruginosa.
• The concurrent use of CVVHDF may mitigate the nephrotoxic risks associated with high-dose aminoglycoside administration.
• This therapeutic strategy holds promise for managing infections caused by challenging multidrug-resistant pathogens.